These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy. Martínez-Sáez O; Gajate Borau P; Alonso-Gordoa T; Molina-Cerrillo J; Grande E Crit Rev Oncol Hematol; 2017 Mar; 111():117-123. PubMed ID: 28259286 [TBL] [Abstract][Full Text] [Related]
4. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731 [TBL] [Abstract][Full Text] [Related]
5. Sensitivity of Stransky LA; Vigeant SM; Huang B; West D; Denize T; Walton E; Signoretti S; Kaelin WG Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2120403119. PubMed ID: 35357972 [TBL] [Abstract][Full Text] [Related]
6. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth. Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364 [TBL] [Abstract][Full Text] [Related]
7. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions. Tella SH; Taïeb D; Pacak K Eur J Cancer; 2017 Nov; 86():1-4. PubMed ID: 28946040 [TBL] [Abstract][Full Text] [Related]
8. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma. Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793 [TBL] [Abstract][Full Text] [Related]
9. 3-[(1 Xu R; Wang K; Rizzi JP; Huang H; Grina JA; Schlachter ST; Wang B; Wehn PM; Yang H; Dixon DD; Czerwinski RM; Du X; Ged EL; Han G; Tan H; Wong T; Xie S; Josey JA; Wallace EM J Med Chem; 2019 Aug; 62(15):6876-6893. PubMed ID: 31282155 [TBL] [Abstract][Full Text] [Related]
10. SHARPIN regulates the development of clear cell renal cell carcinoma by promoting von Hippel-Lindau protein ubiquitination and degradation. Yin R; Liu S Cancer Sci; 2021 Oct; 112(10):4100-4111. PubMed ID: 34339558 [TBL] [Abstract][Full Text] [Related]
11. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. Petrella BL; Brinckerhoff CE Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472 [TBL] [Abstract][Full Text] [Related]
12. HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma. Bacigalupa ZA; Arner EN; Vlach LM; Wolf MM; Brown WA; Krystofiak ES; Ye X; Hongo RA; Landis M; Amason EK; Beckermann KE; Rathmell WK; Rathmell JC J Clin Invest; 2024 Jun; 134(12):. PubMed ID: 38941296 [TBL] [Abstract][Full Text] [Related]
13. ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma. Green YS; Ferreira Dos Santos MC; Fuja DG; Reichert EC; Campos AR; Cowman SJ; Acuña Pilarte K; Kohan J; Tripp SR; Leibold EA; Sirohi D; Agarwal N; Liu X; Koh MY Oncogene; 2022 Oct; 41(42):4709-4723. PubMed ID: 36097192 [TBL] [Abstract][Full Text] [Related]
15. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma. Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458 [TBL] [Abstract][Full Text] [Related]
16. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). Wehn PM; Rizzi JP; Dixon DD; Grina JA; Schlachter ST; Wang B; Xu R; Yang H; Du X; Han G; Wang K; Cao Z; Cheng T; Czerwinski RM; Goggin BS; Huang H; Halfmann MM; Maddie MA; Morton EL; Olive SR; Tan H; Xie S; Wong T; Josey JA; Wallace EM J Med Chem; 2018 Nov; 61(21):9691-9721. PubMed ID: 30289716 [TBL] [Abstract][Full Text] [Related]
17. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma. Gong K; Zhang N; Zhang K; Na Y Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786 [TBL] [Abstract][Full Text] [Related]
18. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124 [TBL] [Abstract][Full Text] [Related]
19. Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma. David JM; Owens TA; Inge LJ; Bremner RM; Rajasekaran AK Mol Cancer Ther; 2014 Apr; 13(4):788-99. PubMed ID: 24493697 [TBL] [Abstract][Full Text] [Related]
20. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α. Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]